Translational challenges in amyotrophic lateral sclerosis therapy with macrophage migration inhibitory factor  

作　　者：Leenor Alfahel Aleksandar Rajkovic Adrian Israelson 

机构地区：[1]Department of Physiology and Cell Biology,Faculty of Health Sciences,Ben-Gurion University of the Negev,Beer Sheva,Israel,The School of Brain Sciences and Cognition,Ben-Gurion University of the Negev,Beer Sheva,Israel

出　　处：《Neural Regeneration Research》2025年第9期2583-2584,共2页中国神经再生研究（英文版）

基　　金：supported by grants from the Israel Science Foundation(ISF#284/19);German Israeli Foundation(GIF#I-116-415.6-2016)(to AI)。

摘　　要：Macrophage migration inhibitory factor(MIF):MIF acts as a pleiotropic inflammatory mediator,playing regulatory roles in innate and adaptive immunity,neuroinflammation,neuroendocrine functions,and nervous system development(Matejuk et al.,2024).In recent years,MIF has attra cted significant inte rest from research groups as a potential target for the treatment of various neurodegenerative diseases,including Alzheimer's disease,Parkinson's disease,multiple sclerosis,and glioblastoma(Matejuk et al.,2024).

关 键 词：IMMUNITY SCLEROSIS 

分 类 号：R744.8[医药卫生—神经病学与精神病学]